| Followers | 19 |
| Posts | 6549 |
| Boards Moderated | 1 |
| Alias Born | 05/23/2019 |
Friday, April 02, 2021 9:46:59 AM
Jim, Can YQU believe this speaking of a time frame. Mind Med Matters just filed their Patent in October 2020 and it is finally posted here YQU Understand. What does your independent voice say about a two year or more window for approval? The WQLF understands there is a heavy backlog at the USPTO since the Chinese invaded us last year YQU Understand. Have Mercy Wolf Ahooooooo
Hey Wolfman, you may wish to go over the sedar filings on this one, the focus would be on time frames and costs, unless it's just a trader for you.
Anyway Kind regards, https://investorshub.advfn.com/boards/read_msg.aspx?message_id=162944627
Recent DFTX News
- Definium Therapeutics to Participate at Upcoming Investor Conferences and Events • Business Wire • 04/09/2026 11:00:00 AM
- New Definium Therapeutics Study Published in the Journal of Mood and Anxiety Disorders Reveals Increasing Prevalence and Burden of Generalized Anxiety Disorder in the United States • Business Wire • 03/31/2026 11:00:00 AM
- Definium Therapeutics Announces New Employee Inducement Grants • Business Wire • 03/30/2026 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/26/2026 10:43:44 PM
- Definium Therapeutics to Host Investor and Analyst Day in New York on April 22, 2026 • Business Wire • 03/26/2026 11:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/25/2026 09:41:22 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/25/2026 09:40:41 PM
- Definium Therapeutics Announces New Employee Inducement Grants • Business Wire • 03/09/2026 08:01:00 PM
- CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions • PR Newswire (US) • 03/09/2026 02:50:00 PM
- CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions • PR Newswire (Canada) • 03/09/2026 02:50:00 PM
- Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments • PR Newswire (US) • 02/27/2026 04:44:00 PM
- Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments • PR Newswire (Canada) • 02/27/2026 04:44:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 09:10:27 PM
- Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates • Business Wire • 02/26/2026 09:01:00 PM
- Definium Therapeutics to Participate at Upcoming Investor Conferences • Business Wire • 02/24/2026 12:01:00 PM
- Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026 • Business Wire • 02/19/2026 09:01:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/17/2026 09:21:24 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/13/2026 01:42:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2026 09:54:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2026 09:53:18 PM
- Definium Therapeutics Announces New Employee Inducement Grants • Business Wire • 02/02/2026 09:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2026 12:30:27 PM
- Definium Therapeutics Appoints Roger Adsett to Board of Directors • Business Wire • 01/29/2026 12:00:00 PM
- Definium Therapeutics Announces New Employee Inducement Grants • Business Wire • 01/26/2026 09:01:00 PM
- Definium Therapeutics Introduces Rerouting Minds, an Educational Campaign Exploring the Potential of Pharmaceutical Lysergide (LSD) in Mental Health Care • Business Wire • 01/20/2026 12:00:00 PM
